Martin Ryser

Responses of Kidney Transplant Recipients to Vaccination and Boosting

Walter D. Park, S. Nair, Hani M. Wadei, Yun Liang et autres

us, nl (code pays fourni par la source)

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data

Leah Andrews, M. Elizabeth Halloran, Lars van der Laan, Yunda Huang et autres

Importance: The test-negative design (TND) has been widely used to assess postmarketing COVID-19 vaccine effectiveness but requires further evaluation for this application. Objective: To determine whether the TND reliably evaluates vaccine effectiveness against symptomatic COVID-19 using placebo-controlled vaccine efficacy randomized clinical trials …

us, gb, be (code pays fourni par la source)

Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial

Sant Muangnoicharoen, Rakpong Wiangcharoen, Saranath Lawpoolsri, Sira Nanthapisal et autres

BACKGROUND: Inactivated whole-virus vaccination elicits immune responses to both SARS-CoV-2 nucleocapsid (N) and spike (S) proteins, like natural infections. A heterologous Ad26.COV2.S booster given at two different intervals after primary BBIBP-CorV vaccination was safe and immunogenic at days 28 and 84, with …

th, kr, be, ca, sg (code pays fourni par la source)

Heterologous Ad26.Cov2.S Booster after Primary Bbibp-Corv Vaccination Against Sars-Cov-2 Infection: 1-Year Follow-Up of a Phase 1/2 Open-Label Trialheterologous Ad26.Cov2.S Booster after Primary Bbibp-Corv Vaccination Against Sars-Cov-2 Infection: 1-Year Follow-Up of a Phase 1/2 Open-Label Trial

Sant Muangnoicharoen, Rakpong Wiangcharoen, Saranath Lawpoolsri, Sira Nanthapisal et autres

th, Nigéria, kr, be, cn, ca (code pays fourni par la source)

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial

Sant Muangnoicharoen, Rakpong Wiangcharoen, Sira Nanthapisal, Supitcha Kamolratakul et autres

BACKGROUND: The inactivated COVID-19 whole-virus vaccine BBIBP-CorV has been extensively used worldwide. Heterologous boosting after primary vaccination can induce higher immune responses against SARS-CoV-2 than homologous boosting. The safety and immunogenicity after 28 days of a single Ad26.COV2.S booster dose given at …

th, kr, be, ca, sg (code pays fourni par la source)

Single Ad26.COV2.S Booster Dose Following Two Doses of BBIBP-CorV Vaccine Against SARS-CoV-2 Infection in Adults: Day 28 Results of a Phase 1/2 Open-Label Trial

Sant Muangnoicharoen, Rakpong Wiangcharoen, Sira Nanthapisal, Supitcha Kamolratakul et autres

th, Nigéria, kr, be, cn, sg, ca (code pays fourni par la source)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff, Mathieu Le Gars et autres

be, nl, gb, de (code pays fourni par la source)

Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccine

Mathieu Le Gars, Jenny Hendriks, Jerald Sadoff, Martin Ryser et autres

Since its emergence in late 2019, the coronavirus disease 2019 (COVID-19) pandemic has caused substantial morbidity and mortality. Despite the availability of efficacious vaccines, new variants with reduced sensitivity to vaccine-induced protection are a troubling new reality. The Ad26.COV2.S vaccine is a …

nl, be (code pays fourni par la source)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas et autres

BACKGROUND: The Ad26.COV2.S vaccine was highly effective against severe-critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. METHODS: viral particles) or placebo. The primary end points were vaccine efficacy against moderate to severe-critical Covid-19 with onset …

us, be, nl, Afrique du Sud, jp (code pays fourni par la source)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas et autres

BACKGROUND: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. METHODS: viral particles) or placebo. The primary end points were vaccine efficacy against moderate …

us, be (code pays fourni par la source)

Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study

Joseph E. Tota, Frank Struyf, Allan Hildesheim, Paula González et autres

Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This …

us, be, cr, fr, nl, fi (code pays fourni par la source)

Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials

Joseph E. Tota, Frank Struyf, Joshua N. Sampson, Paula González et autres

BACKGROUND: The AS04-adjuvanted HPV16/18 (AS04-HPV16/18) vaccine provides excellent protection against targeted human papillomavirus (HPV) types and a variable degree of cross-protection against others, including types 6/11/31/33/45. High efficacy against any cervical intraepithelial neoplasia grade 3 or greater (CIN3+; >90%) suggests that lower …

us, be, cr, fr, nl (code pays fourni par la source)